Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CytoDyn ( (CYDY) ) has shared an update.
CytoDyn, a biotechnology company that develops pharmaceutical therapies and uses structured financing to support its operations, has restructured key debt obligations originally issued in 2021 as secured convertible promissory notes totaling $57 million. These notes, first entered on April 2 and April 23, 2021, had previously been extended to mature in April 2026 before the latest modification.
On March 24, 2026, CytoDyn and the holders of its two secured convertible notes agreed to extend each note’s maturity date by 36 months to April 5, 2029 and April 23, 2029, respectively. In return, the company will make combined monthly payments of $1 million in common stock, priced at the lower of the prior day’s close or a five-day average, and the annual interest rate on each note has been reduced to 5%, easing cash interest costs while increasing potential equity dilution for existing shareholders.
More about CytoDyn
CytoDyn is a biotechnology company that develops pharmaceutical therapies, focusing on treatments that are often financed through structured securities and convertible debt arrangements. The company actively manages its capital structure through negotiated extensions and modifications of its outstanding notes to support ongoing operations and development efforts.
Average Trading Volume: 1,711,545
Technical Sentiment Signal: Buy
Current Market Cap: $354.2M
Learn more about CYDY stock on TipRanks’ Stock Analysis page.